Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an announcement.
Qyuns Therapeutics Co., Ltd. reported that its extraordinary general meeting held on 19 December 2025 in Taizhou, Jiangsu, was duly convened in compliance with PRC law and the company’s articles, with a turnout representing over 70% of H shares with voting rights. Shareholders overwhelmingly approved, by poll, the renewal of the new annual caps for 2026–2028 under the QX001S Framework Agreement for continuing connected transactions, despite the required abstention of significant shareholder Huadong Medicine’s subsidiaries, effectively clearing the way for the company to continue its related-party cooperation arrangements and providing clearer visibility on its transaction limits and governance alignment for the coming three financial years.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong, focusing on the research, development and commercialization of therapeutics, with its H shares traded under stock code 2509. The company operates within a regulated framework under PRC company law and Hong Kong listing rules, with Huadong Medicine, through its subsidiaries, holding a significant minority stake in its H-share capital.
Average Trading Volume: 589,540
Technical Sentiment Signal: Hold
Current Market Cap: HK$4.17B
See more data about 2509 stock on TipRanks’ Stock Analysis page.